微生物発酵技術 - 市場考察、競合情勢、市場予測（2032年）

世界の微生物発酵技術の市場規模は、2024年に339億5,610万米ドルであり、2025年～2032年の予測期間にCAGRで5.24%の成長が見込まれます。市場は、がんやHIV、B型肝炎、C型肝炎、インフルエンザなどの感染症などの慢性疾患の有病率の上昇により大きく成長しています。さらに、細胞療法、モノクローナル抗体、組換えタンパク質、遺伝子療法などの先進の治療薬に対する需要の増加が、市場の拡大をさらに後押ししています。合成生物学や精密発酵の技術的進歩も、生産効率、拡張性、品質の向上に極めて重要な役割を果たしています。これらの要因は、バイオプロセスにおける継続的な技術革新と組み合わさり、予測期間（2025年～2032年）に微生物発酵技術市場を大きく牽引する見込みです。

微生物発酵技術の市場力学

微生物発酵技術市場は、主に世界中での慢性疾患と感染症の有病率の上昇によって力強い成長を示しています。世界保健機関（WHO、2024）によると、2022年に約3,900万人がHIVとともに生活しており、その内訳は成人（15歳以上）が約3,750万人、小児（15歳未満）が約150万人です。さらに、同じ資料によれば、世界全体で3億400万人がB型肝炎とC型肝炎に感染しており、B型肝炎の罹患者は2億5,400万人、C型肝炎の罹患者は5,000万人です。

HIVとウイルス性肝炎の世界的負担の増大により、抗ウイルス薬、モノクローナル抗体、治療用ワクチンなど、発酵ベースのバイオ医薬品に対する需要が急増しています。微生物発酵は、これらの治療薬の大規模で費用対効果の高い生産を可能にする上で重要な役割を果たしており、患者のアドヒアランスと治療成績の向上を目指す長時間作用型注射剤や次世代生物製剤の進歩を支えています。

感染症だけでなく、がんや自己免疫疾患などの慢性疾患の有病率の増加が、微生物発酵技術に大きく依存する細胞療法、モノクローナル抗体、組換えタンパク質、遺伝子治療領域への需要を促進しています。例えばモノクローナル抗体は、腫瘍学や免疫学において不可欠なものとなっており、その市場は今後数年で大きく成長すると予測されています。同様に、組換えタンパク質セグメントは、代謝異常、血液疾患、希少遺伝性疾患の治療に重要な役割を果たすため、急速に拡大しています。

以前は治療不可能であった遺伝性疾患の治療に革命をもたらしている遺伝子治療も、ウイルスベクターやプラスミドDNAの生産を通じて微生物発酵技術の恩恵を受けています。合成生物学と精密発酵における革新は、生産効率、製品の歩留まり、品質をさらに向上させ、より精巧な標的治療の開発を支えています。

こうした成長促進要因にもかかわらず、市場は課題にも直面しています。規制当局の厳しい承認プロセス、治療用タンパク質を安定的に発現する歩留まりのよい微生物株の開発の複雑性、スケーラビリティの問題などが大きなハードルとなっています。大規模生産における一貫した品質と有効性の確保は、依然として技術の進歩とプロセスの最適化を必要とする重要な分野です。

とはいえ、疾患の有病率の上昇、バイオ医薬品需要の増加、微生物発酵における技術革新の相互作用により、予測期間（2025年～2032年）に市場は大きく成長する見込みであり、研究開発への継続的な投資により既存の課題が克服され、市場の将来性がさらに拡大する可能性が高いです。

北米が微生物発酵技術市場全体を独占すると予測される

北米は予測期間（2025年～2032年）に微生物発酵技術市場を独占すると予測されます。この地域のリーダーシップは、感染症（結核、インフルエンザ、新興病原体など）の負担の増加、がん有病率の増加、堅調な製品開発活動、主要メーカーのプレゼンス、確立された医療インフラなど、複数の要因によるものです。

Public Health Agency of Canada（2024）によると、カナダには2022年に1,971人の活動性結核患者が存在しました。この地域における感染症負担の増大が、発酵由来の抗生物質やワクチンの需要を押し上げています。特に、薬剤耐性（AMR）の高まりは、次世代の抗生物質やバイオ医薬品への投資を強化し、発酵ベースのワクチンの生産を、大流行を防ぐ重要なツールとして位置付けています。効果的な治療法に対するニーズの高まりが、微生物発酵技術の進歩に拍車をかけています。

当レポートでは、世界の微生物発酵技術市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 微生物発酵技術市場レポートのイントロダクション

第2章 微生物発酵技術市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 微生物発酵技術市場の主な要因の分析

• 微生物発酵技術市場の促進要因
• 微生物発酵技術市場の抑制要因と課題
• 微生物発酵技術市場の機会

第6章 微生物発酵技術市場のポーターのファイブフォース分析

第7章 微生物発酵技術市場の評価

• 製品タイプ別
  • 抗生物質
  • プロバイオティクス
  • モノクローナル抗体
  • バイオシミラー
  • 組み換えタンパク質・ワクチン
  • 酵素
  • その他
• エンドユーザー別
  • 製薬・バイオテクノロジー産業
  • 開発業務受託機関（CRO）
  • CMO・CDMO
  • 学術・研究機関
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 微生物発酵技術市場の企業と製品のプロファイル

• Novozymes A/S
• Lonza Group AG
• Koninklijke DSM N.V.
• Biocon Limited
• Ajinomoto Co., Inc.
• Evonik Industries AG
• Intralytix, Inc.
• UAS Laboratories LLC
• Second Genome, Inc.
• Chr. Hansen Holding A/S
• Ginkgo Bioworks
• Amyris, Inc.
• Lesaffre
• BioVectra Inc.
• TerraVia Holdings, Inc.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Microbial Fermentation Technology Market in Global (2022-2032)
• Table 3: Microbial Fermentation Technology Market in Global by Product Type (2022-2032)
• Table 4: Microbial Fermentation Technology Market in Global by End-User (2022-2032)
• Table 5: Microbial Fermentation Technology Market in Global by Geography (2022-2032)
• Table 6: Microbial Fermentation Technology Market in North America (2022-2032)
• Table 7: Microbial Fermentation Technology Market in the United States (2022-2032)
• Table 8: Microbial Fermentation Technology Market in Canada (2022-2032)
• Table 9: Microbial Fermentation Technology Market in Mexico (2022-2032)
• Table 10: Microbial Fermentation Technology Market in Europe (2022-2032)
• Table 11: Microbial Fermentation Technology Market in France (2022-2032)
• Table 12: Microbial Fermentation Technology Market in Germany (2022-2032)
• Table 13: Microbial Fermentation Technology Market in United Kingdom (2022-2032)
• Table 14: Microbial Fermentation Technology Market in Italy (2022-2032)
• Table 15: Microbial Fermentation Technology Market in Spain (2022-2032)
• Table 16: Microbial Fermentation Technology Market in Rest of Europe (2022-2032)
• Table 17: Microbial Fermentation Technology Market in Asia-Pacific (2022-2032)
• Table 19: Microbial Fermentation Technology Market in China (2022-2032)
• Table 19: Microbial Fermentation Technology Market in Japan (2022-2032)
• Table 20: Microbial Fermentation Technology Market in India (2022-2032)
• Table 21: Microbial Fermentation Technology Market in Australia (2022-2032)
• Table 22: Microbial Fermentation Technology Market in South Korea (2022-2032)
• Table 23: Microbial Fermentation Technology Market in Rest of Asia-Pacific (2022-2032)
• Table 24: Microbial Fermentation Technology Market in Rest of the World (2022-2032)
• Table 25: Microbial Fermentation Technology Market in the Middle East (2022-2032)
• Table 26: Microbial Fermentation Technology Market in Africa (2022-2032)
• Table 27: Microbial Fermentation Technology Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Microbial Fermentation Technology Market in Global (2022-2032)
• Figure 3: Microbial Fermentation Technology Market in Global by Product Type (2022-2032)
• Figure 4: Microbial Fermentation Technology Market in Global by End-User (2022-2032)
• Figure 5: Microbial Fermentation Technology Market in Global by Geography (2022-2032)
• Figure 6: Microbial Fermentation Technology Market in North America (2022-2032)
• Figure 7: Microbial Fermentation Technology Market in the United States (2022-2032)
• Figure 8: Microbial Fermentation Technology Market in Canada (2022-2032)
• Figure 9: Microbial Fermentation Technology Market in Mexico (2022-2032)
• Figure 10: Microbial Fermentation Technology Market in Europe (2022-2032)
• Figure 11: Microbial Fermentation Technology Market in France (2022-2032)
• Figure 12: Microbial Fermentation Technology Market in Germany (2022-2032)
• Figure 13: Microbial Fermentation Technology Market in United Kingdom (2022-2032)
• Figure 14: Microbial Fermentation Technology Market in Italy (2022-2032)
• Figure 15: Microbial Fermentation Technology Market in Spain (2022-2032)
• Figure 16: Microbial Fermentation Technology Market in Rest of Europe (2022-2032)
• Figure 17: Microbial Fermentation Technology Market in Asia-Pacific (2022-2032)
• Figure 18: Microbial Fermentation Technology Market in China (2022-2032)
• Figure 19: Microbial Fermentation Technology Market in Japan (2022-2032)
• Figure 20: Microbial Fermentation Technology Market in India (2022-2032)
• Figure 21: Microbial Fermentation Technology Market in Australia (2022-2032)
• Figure 22: Microbial Fermentation Technology Market in South Korea (2022-2032)
• Figure 23: Microbial Fermentation Technology Market in Rest of Asia-Pacific (2022-2032)
• Figure 24: Microbial Fermentation Technology Market in Rest of the World (2022-2032)
• Figure 25: Microbial Fermentation Technology Market in the Middle East (2022-2032)
• Figure 26: Microbial Fermentation Technology Market in Africa (2022-2032)
• Figure 27: Microbial Fermentation Technology Market in South America (2022-2032)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Microbial Fermentation Technology Market by Product Type (Antibiotics, Probiotics, Monoclonal Antibodies, Biosimilar, Recombinant Proteins & Vaccines, Enzymes, and Others), End-User (Pharmaceutical & Biotechnology Industry, Contract Research Organizations (CROs), CMOs & CDMOs, and Academic & Research Institutions), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2032 owing to the increased prevalence of chronic disorders & infectious diseases and growing demand for cell therapy monoclonal antibodies, recombinant proteins, and gene therapies globally.

The microbial fermentation technology market was valued at USD 33,956.10 million in 2024, growing at a CAGR of 5.24% during the forecast period from 2025 to 2032. The microbial fermentation technology market is witnessing substantial growth, driven by the rising prevalence of chronic disorders such as cancer and infectious diseases, including HIV, hepatitis B and C, and influenza. Additionally, increasing demand for advanced therapeutics such as cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies is further propelling market expansion. Technological advancements in synthetic biology and precision fermentation are also playing a pivotal role in enhancing production efficiency, scalability, and product quality. These factors, combined with ongoing innovations in bioprocessing, are expected to drive the microbial fermentation technology market significantly during the forecast period (2025-2032).

Microbial Fermentation Technology Market Dynamics:

The microbial fermentation technology market is experiencing robust growth, primarily driven by the rising prevalence of chronic diseases and infectious conditions globally. According to the World Health Organization (WHO, 2024), nearly 39 million people were living with HIV in 2022, with approximately 37.5 million adults (aged 15 and above) and around 1.5 million children (under 15 years). Additionally, the same source reported that 304 million people were infected with hepatitis B and C globally, with 254 million affected by hepatitis B and 50 million by hepatitis C.

The increasing global burden of HIV and viral hepatitis has led to a surge in demand for fermentation-based biopharmaceuticals, including antiviral drugs, monoclonal antibodies, and therapeutic vaccines. Microbial fermentation plays a crucial role in enabling large-scale, cost-effective production of these treatments, supporting advancements in long-acting injectables and next-generation biologics aimed at improving patient adherence and therapeutic outcomes.

Beyond infectious diseases, the growing prevalence of chronic conditions such as cancer and autoimmune disorders is fueling demand for cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies sectors that heavily rely on microbial fermentation technology. Monoclonal antibodies, for instance, have become essential in oncology and immunology, with their market projected to witness significant growth in the coming years. Similarly, the recombinant proteins segment is expanding rapidly due to their critical role in treating metabolic disorders, hematological diseases, and rare genetic conditions.

Gene therapies, which are revolutionizing the treatment landscape for previously untreatable genetic diseases, also benefit from microbial fermentation technology through the production of viral vectors and plasmid DNA. Innovations in synthetic biology and precision fermentation are further enhancing production efficiency, product yield, and quality, thereby supporting the development of more sophisticated and targeted therapies.

Despite these growth drivers, the market faces challenges. Stringent regulatory approval processes, the complexity of developing high-yield microbial strains with stable expression of therapeutic proteins, and scalability issues pose significant hurdles. Ensuring consistent quality and efficacy in large-scale production remains a key area requiring technological advancement and process optimization.

Nevertheless, the interplay of rising disease prevalence, increasing demand for biopharmaceuticals, and technological innovations in microbial fermentation is expected to propel the market significantly during the forecast period (2025-2032), with continuous investments in R&D likely to overcome existing challenges and further expand market potential.

Microbial Fermentation Technology Market Segment Analysis:

Microbial Fermentation Technology Market by Product Type (Antibiotics, Probiotics, Monoclonal Antibodies, Biosimilar, Recombinant Proteins & Vaccines, Enzymes, and Others), End-User (Pharmaceutical & Biotechnology Industry, Contract Research Organizations (CROs), CMOs & CDMOs, and Academic & Research Institutions), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the microbial fermentation technology market, the antibiotics category is projected to hold the largest revenue share in 2024. This dominance is primarily driven by the increasing global demand for antibiotics in healthcare, rising concerns over antimicrobial resistance (AMR), advancements in fermentation technologies, and substantial government and institutional funding for research and development (R&D).

According to the World Health Organization (WHO), bacterial infections continue to be a leading cause of morbidity and mortality worldwide, with lower respiratory infections ranking among the top causes of death. This escalating health burden fuels the demand for fermentation-derived antibiotics such as penicillins, cephalosporins, and macrolides. The Centers for Disease Control and Prevention (CDC) further reports that at least 1.27 million people die annually from antibiotic-resistant infections. This alarming statistic has prompted pharmaceutical companies to expedite the development of next-generation antibiotics, leveraging microbial fermentation, particularly from actinomycetes (e.g., Streptomyces) and fungi (e.g., Penicillium).

Technological innovations are further catalyzing market growth. Advances in bioprocess optimization, AI-driven bioreactors, genome editing technologies (such as CRISPR-Cas9), and synthetic biology have significantly enhanced the yield, purity, and cost-effectiveness of antibiotic production. Major pharmaceutical players including Lonza, Pfizer, and Novartis have heavily invested in automated microbial fermentation platforms, enabling more efficient large-scale production while ensuring profitability.

Global health initiatives and regulatory bodies are also playing a crucial role in strengthening the antibiotics market. Organizations such as the Global Antibiotic Research & Development Partnership (GARDP), the U.S. Biomedical Advanced Research and Development Authority (BARDA), and the European Innovative Medicines Initiative (IMI) are actively providing funding and support to accelerate antibiotic R&D. These efforts are vital in addressing the AMR crisis and ensuring the availability of effective antimicrobial therapies.

Given the convergence of rising infectious disease prevalence, increasing AMR challenges, technological advancements, and strong governmental and institutional backing, the antibiotics category is poised for considerable growth. This upward trend is expected to significantly contribute to the overall expansion of the microbial fermentation technology market during the forecast period (2025-2032).

North America is expected to dominate the overall microbial fermentation technology market:

North America is anticipated to dominate the microbial fermentation technology market during the forecast period (2025-2032). This regional leadership is attributed to several factors, including the rising burden of infectious diseases (such as tuberculosis, influenza, and emerging pathogens), increasing cancer prevalence, robust product development activities, the presence of key manufacturers, and a well-established healthcare infrastructure.

According to the Public Health Agency of Canada (2024), there were 1,971 active tuberculosis cases in Canada in 2022. The growing burden of infectious diseases in the region has driven the demand for fermentation-derived antibiotics and vaccines. Notably, rising antimicrobial resistance (AMR) has intensified investments in next-generation antibiotics and biopharmaceuticals, positioning fermentation-based vaccine production as a vital tool for outbreak control. This heightened need for effective therapies has spurred advancements in microbial fermentation technologies.

Cancer prevalence in North America further fuels market growth. The National Cancer Institute (2024) estimates that 2 million new cancer cases will be diagnosed in the U.S. by the end of 2024. Additionally, data from the Global Cancer Observatory (2024) reveals that in 2022, the U.S. accounted for 89.1% of all regional cancer cases, while Canada represented 10.9%. This rising cancer burden has amplified the demand for microbial fermentation technologies used in producing biopharmaceuticals, monoclonal antibodies, recombinant proteins, and gene therapies. The increased use of plasmid DNA, viral vectors, and microbiome-based treatments particularly in oncology is driving fermentation-based biomanufacturing. As precision medicine and immunotherapies gain traction, the reliance on fermentation technology for scalable, high-quality production of advanced therapeutics continues to grow.

Moreover, North America benefits from the presence of major market players actively advancing microbial fermentation technologies. Leading companies in the region are leveraging innovations in bioprocess optimization, AI-driven bioreactors, and synthetic biology to improve product yield, quality, and cost-effectiveness. The availability of a well-established healthcare infrastructure, coupled with strong regulatory support and government funding, further accelerates the research, development, and commercialization of fermentation-derived products.

Collectively, these factors create a highly conducive environment for market growth, positioning North America as the leading region in the microbial fermentation technology market throughout the forecast period (2025-2032).

Microbial Fermentation Technology Market key players:

Some of the key market players operating in the microbial fermentation technology market include Novozymes A/S, Lonza Group AG, Koninklijke DSM N.V., Biocon Limited, Ajinomoto Co., Inc., Evonik Industries AG, Intralytix, Inc., UAS Laboratories LLC, Second Genome, Inc., Chr. Hansen Holding A/S, Ginkgo Bioworks, Amyris, Inc., Lesaffre, BioVectra Inc.TerraVia Holdings, Inc., and others.

Recent Developmental Activities in the Microbial Fermentation Technology Market:

• In June 2024, Danone, Michelin, DMC Biotechnologies, and Credit Agricole Centre France collaborated to establish the Biotech Open Platform, a cutting-edge biotechnology hub aimed at advancing large-scale precision fermentation. This initiative enhanced the development of bio-based materials and ingredients by leveraging advanced microbial fermentation processes.
• In March 2024, Novel Bio, a leader in next-generation biomanufacturing technologies for plasmid DNA in genetic medicines, announced a partnership with Culture Biosciences to advance scalable fermentation process development for its proprietary NBx Platform(TM).

Key Takeaways from the Microbial Fermentation Technology Market Report Study

• Market size analysis for current microbial fermentation technology market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the microbial fermentation technology market
• Various opportunities available for the other competitors in the microbial fermentation technology market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current microbial fermentation technology market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for microbial fermentation technology market growth in the coming future?

Target audience who can be benefited from this Microbial Fermentation Technology Market Report Study

• Microbial fermentation technology providers
• Research organizations and consulting companies
• Microbial fermentation technology-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in microbial fermentation technology
• Various end-users who want to know more about the microbial fermentation technology market and the latest developments in the microbial fermentation technology market

Frequently Asked Questions for the Microbial Fermentation Technology Market:

1. What is Microbial Fermentation Technology?

• Microbial fermentation technology refers to the use of microorganisms such as bacteria, fungi, and yeast to produce biopharmaceuticals, antibiotics, vaccines, gene therapy vectors, and microbiome-based therapeutics through controlled fermentation processes. This technology enables the large-scale production of monoclonal antibodies, recombinant proteins, enzymes, plasmid DNA, and live biotherapeutics essential for treating various diseases, including cancer, metabolic disorders, and infectious diseases.

2. What is the market for Microbial Fermentation Technology?

• The microbial fermentation technology market was valued at USD 33,956.10 million in 2024, growing at a CAGR of 5.24% during the forecast period from 2025 to 2032.

3. What are the drivers for the Microbial Fermentation Technology market?

• The microbial fermentation technology market is experiencing significant growth due to the increased prevalence of chronic disorders including cancer & infectious diseases such as HIV, hepatitis B & C, and influenza, growing demand for cell therapy monoclonal antibodies, recombinant proteins, and gene therapies, advancements in synthetic biology & precision fermentation, among others that are expected to drive the microbial fermentation technology market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the Microbial Fermentation Technology market?

• Some of the key market players operating in the Microbial Fermentation Technology market include Novozymes A/S, Lonza Group AG, Koninklijke DSM N.V., Biocon Limited, Ajinomoto Co., Inc., Evonik Industries AG, Intralytix, Inc., UAS Laboratories LLC, Second Genome, Inc., Chr. Hansen Holding A/S, Ginkgo Bioworks, Amyris, Inc., Lesaffre, BioVectra Inc.TerraVia Holdings, Inc., and others.

5. Which region has the highest share in the Microbial Fermentation Technology market?

• Among all the regions, North America is estimated to hold a significant revenue share in the microbial fermentation technology market. This domination is due to the growing burden of infectious diseases including tuberculosis, outbreaks of influenza, emerging pathogens, increasing instances of cancer, growing product developmental activities, presence of key manufacturers, presence of well-established healthcare infrastructure, among others that are expected to fuel the microbial fermentation technology market in the region during the forecast period from 2025 to 2032.

Table of Contents

1. Microbial Fermentation Technology Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Microbial Fermentation Technology Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Microbial Fermentation Technology Market Key Factors Analysis

• 5.1. Microbial Fermentation Technology Market Drivers
  • 5.1.1. Increased prevalence of chronic disorders and infectious diseases
  • 5.1.2. Growing demand for cell therapy monoclonal antibodies, recombinant proteins, and gene therapies
  • 5.1.3. Advancements in synthetic biology & precision fermentation
• 5.2. Microbial Fermentation Technology Market Restraints and Challenges
  • 5.2.1. Complex regulatory framework
  • 5.2.2. Developing high-yield microbial strains with stable expression of therapeutic proteins and biologics
• 5.3. Microbial Fermentation Technology Market Opportunities
  • 5.3.1. Innovations in AI-driven strain engineering, metabolic optimization, and automated bioreactors
  • 5.3.2. Expansion in plasmid DNA, viral vector production, and CRISPR-based therapies

6. Microbial Fermentation Technology Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Microbial Fermentation Technology Market Assessment

• 7.1. By Product Type
  • 7.1.1. Antibiotics
  • 7.1.2. Probiotics
  • 7.1.3. Monoclonal Antibodies
  • 7.1.4. Biosimilar
  • 7.1.5. Recombinant Proteins & Vaccines
  • 7.1.6. Enzymes
  • 7.1.7. Others
• 7.2. By End-User
  • 7.2.1. Pharmaceutical & Biotechnology Industry
  • 7.2.2. Contract Research Organizations (CROs)
  • 7.2.3. CMOs & CDMOs
  • 7.2.4. Academic & Research Institutions
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.1.2. Canada Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.1.3. Mexico Microbial Fermentation Technology Market Size in USD million (2022-2032)
  • 7.3.2. Europe
    • 7.3.2.1. France Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.2.2. Germany Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.2.3. United Kingdom Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.2.4. Italy Microbial Fermentation Technology market size in USD million (2022-2032)
    • 7.3.2.5. Spain Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.2.6. Rest of Europe Microbial Fermentation Technology Market Size in USD million (2022-2032)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.3.2. Japan Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.3.3. India Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.3.4. Australia Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.3.5. South Korea Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.3.6. Rest of Asia-Pacific Microbial Fermentation Technology Market Size in USD million (2022-2032)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.4.2. Africa Microbial Fermentation Technology Market Size in USD million (2022-2032)
    • 7.3.4.3. South America Microbial Fermentation Technology Market Size in USD million (2022-2032)

8. Microbial Fermentation Technology Market Company and Product Profiles

• 8.1. Novozymes A/S
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Lonza Group AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Koninklijke DSM N.V.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Biocon Limited
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Ajinomoto Co., Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Evonik Industries AG
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Intralytix, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. UAS Laboratories LLC
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Second Genome, Inc.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Chr. Hansen Holding A/S
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Ginkgo Bioworks
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Amyris, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Lesaffre
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. BioVectra Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. TerraVia Holdings, Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us